✨
AI Summary
- Enfortumab vedotin plus pembrolizumab showed strongest EFS, OS, and PCR improvements.
- Network meta-analysis compared neoadjuvant options for cisplatin-eligible MIBC.
- Perioperative trial design limits direct attribution to neoadjuvant phase alone.
Guests on This Episode
CM
Chiara Mercinelli
1 podcast appearance